Please login to the form below
oral anticoagulant
This page shows the latest oral anticoagulant news and features for those working in and with pharma, biotech and healthcare.
UPDATED: BMS completes $13.1bn acquisition of MyoKardia
This includes the company’s oral anticoagulant Eliquis (apixaban), BMS’ second biggest product after cancer immunotherapy Opdivo (nivolumab). ... However, BMS is facing competition from generic rivals of Eliquis – in December 2019, the FDA approved
Latest news
-
FDA clears first generics of Pfizer/BMS’ anticoagulant Eliquis
These approvals mark the first generic approvals of a direct oral anticoagulant,” said Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research (CDER). ... Unlike older anticoagulants like warfarin, “direct oral
-
Pfizer CEO reckons rebates will disappear, and that’s a positive
its innovative health unit and particularly Xeljanz – up 38% to $463m in the quarter – as well as breast cancer drug Ibrance (palbociclib) which rose 20% to $1bn and novel oral anticoagulant
-
Pharma sales help Bayer escape the worst from a bumpy 2017
Its pharma business was once again led by Bayer’s top-seller Xarelto, with sales of the oral anticoagulant rising 12.6% to 3.6bn, and eye drug Eylea, which was
-
Bad news for Portola as CHMP considers Factor Xa drugs
Portola Pharmaceuticals’ efforts to secure approval for its novel oral anticoagulant (NOAC) and reversal agent in Europe have hit another snag. ... for betrixaban, its oral, once-daily Factor Xa inhibitor, as well as antidote drug andexanet alfa.
-
Joerg Moeller to head Bayer R&D after operational shake-up
It will also highlight its plans to expand the use of novel oral anticoagulant (NOAC) Xarelto (rivaroxaban) into coronary and peripheral artery disease, along with new-generation anticoagulants in mid-phase
More from news
Approximately 0 fully matching, plus 78 partially matching documents found.
Latest Intelligence
-
Digital disruption in market access
publication of the first direct oral anticoagulant technology appraisal, we are not yet there.
-
Modern anticoagulants threaten status quo
Warfarin, an oral vitamin K antagonist (VKA) approved in the early 1950s, has ruled the anticoagulant market for nearly six decades. ... Delays and withdrawals. Eli Lilly was developing a once-daily, piperazine class, oral anticoagulant called LY 517717
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
-
B2B media account director
-
Competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- First trial of a vaccine against Alzheimer’s launches
- Merck enters agreement with Hanmi for investigational NASH drug
- Novo Nordisk growth takes a hit with China deal
- Omicron prompts global action
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Sanofi to buy acne specialist Origimm
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- First von Willebrand disease therapy heads new FDA approvals
- Sanofi to buy acne specialist Origimm
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- David Hunt launches independent agency The Considered
PMHub
Dice Medical Communications
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
